Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) - Total Assets
Based on the latest financial reports, Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) holds total assets worth CN¥1.32 Billion CNY (≈ $193.73 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 300534 net asset value for net asset value and shareholders' equity analysis.
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's total assets have evolved over time, based on quarterly financial data.
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's total assets of CN¥1.32 Billion consist of 48.2% current assets and 51.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 20.7% |
| Accounts Receivable | CN¥235.95 Million | 16.8% |
| Inventory | CN¥115.82 Million | 8.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥62.81 Million | 4.5% |
| Goodwill | CN¥13.72 Million | 1.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Gansu Longshenrongfa Pharmaceutical Indu stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's current assets represent 48.2% of total assets in 2024, a decrease from 76.6% in 2011.
- Cash Position: Cash and equivalents constituted 20.7% of total assets in 2024, up from 8.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 1.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 16.8% of total assets.
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Competitors by Total Assets
Key competitors of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.60 | 1.29 | 3.22 |
| Quick Ratio | 1.26 | 1.08 | 2.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥218.79 Million | CN¥149.16 Million | CN¥229.62 Million |
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd - Advanced Valuation Insights
This section examines the relationship between Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.30 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | 4.9% |
| Total Assets | CN¥1.40 Billion |
| Market Capitalization | $420.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's assets grew by 4.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (2011–2024)
The table below shows the annual total assets of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.40 Billion ≈ $205.20 Million |
+4.91% |
| 2023-12-31 | CN¥1.34 Billion ≈ $195.59 Million |
+46.44% |
| 2022-12-31 | CN¥912.79 Million ≈ $133.57 Million |
+10.77% |
| 2021-12-31 | CN¥824.07 Million ≈ $120.59 Million |
-4.91% |
| 2020-12-31 | CN¥866.66 Million ≈ $126.82 Million |
+6.98% |
| 2019-12-31 | CN¥810.15 Million ≈ $118.55 Million |
+4.06% |
| 2018-12-31 | CN¥778.51 Million ≈ $113.92 Million |
-0.47% |
| 2017-12-31 | CN¥782.23 Million ≈ $114.46 Million |
+2.46% |
| 2016-12-31 | CN¥763.48 Million ≈ $111.72 Million |
+18.05% |
| 2015-12-31 | CN¥646.74 Million ≈ $94.64 Million |
+35.16% |
| 2014-12-31 | CN¥478.49 Million ≈ $70.02 Million |
+5.40% |
| 2013-12-31 | CN¥453.96 Million ≈ $66.43 Million |
+54.13% |
| 2012-12-31 | CN¥294.53 Million ≈ $43.10 Million |
+144.43% |
| 2011-12-31 | CN¥120.49 Million ≈ $17.63 Million |
-- |
About Gansu Longshenrongfa Pharmaceutical Industry Co Ltd
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD researches, develops, produces, and sells traditional Chinese medicines, medical devices, and health products in China and internationally. It also engages in the cultivation, processing, and sale of chemical drugs and medicinal herbs, as well as pharmaceutical distribution, testing, and inspection services. The company was founded in 2002 and … Read more